ANIXA BIOSCIENCES, INC. Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments
ANIXA BIOSCIENCES, INC. (ANIX) reported Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments of -$62.83 thousand for the 12-month period ending 2014-10-31, per its 10-K filed 2015-12-23.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2015-12-23
- ANIXA BIOSCIENCES, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2014 was -$62.83K.
- ANIXA BIOSCIENCES, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2013 was -$1.18M.
- ANIXA BIOSCIENCES, INC. available-for-sale securities, gross realized gain (loss), excluding other than temporary impairments for fiscal 2011 was -$1.79M.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month | Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments 12 month as first filed |
|---|---|---|
| 2014-10-31 | -$62.83K 10-K · filed 2015-12-23 | |
| 2013-10-31 | -$1.18M 10-K · filed 2015-01-29 | $1.18M 10-K/A · filed 2014-01-17 |
| 2011-10-31 | -$1.79M 10-K · filed 2013-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |